Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q2 2019 Earnings Presentation
18 slides from Bonesupport Holding Ab's earnings presentation, July 2019
Slide 1: BONESUPPORT Q2(19)
BONESUPPORT™ Q2(19) July 2019 Emil Billbäck, CEO Håkan Johansson CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: Financial highlights / Operational highlights
Financial highlights • Q2(19) net sales SEK37.3m, +32% YoY • EU & ROW: +59% Y/Y to SEK22.5m • CERAMENT G & V: +64% • North America: Q/Q growth with +28% • Operating Result: -47.8 mSEK, influenced by provision for product returns Operational highlights • Solidifying the North American distribution ne
Slide 4: Establishing new foundation for North America; strong growth in Europe & ROW
Establishing new foundation for North America Strong growth in Europe & ROW Growth traction EUROW H1 2018: +14% Q3 2018: +29% Q4 2018: +32% EUROW 2019 Q2 Q1 2019: +41% growth: +59% Q2 2019: +59% 4
Slide 5: EUROW – Strong sales growth with antibiotic eluting products
EUROW – Strong sales growth with antibiotic eluting products Q1 2019 • Total sales of SEK22.5m, growth of 59% • Antibiotic eluting products growth of 64% Highlights • Increasing use of CERAMENT on the basis of compelling clinical evidence • Completing German & UK recruitments. Finally at full set up
Slide 6: North America – Progressing well. Showing growth Y/Y
North America – Progressing well. Showing growth Y/Y Q2 2019 • Total sales of SEK14.8m, up 28% from 11.5m in Q1(19) • Growth of +6% Y/Y New distribution network • Solidifying the “all states coverage” with 40 independent distributors, six have been replaced • Sales picking up well at end of Q2 follo
Slide 7: Focusing our R&D efforts
Focusing our R&D efforts CERAMENT plus bisphosphonate • Improves bone regeneration and bone density • Low-healing bone defects and fractures induced by low bone density CERAMENT plus DBM • Osteoconductive and osteoinductive properties • Trauma and foot & ankle surgery • Replaces the previous project
Slide 8: CERAMENT G significantly improves outcome in open tibia fractures
CERAMENT G significantly improves outcome in open tibia fractures New prospective study on patients with severe tibia fractures ▪ 51 patients with type IIIB fracture (open fracture with extensive soft tissue injury and bone exposure). ▪ These type of fractures are documented to have an infection rat
Slide 9: Financial Review
Financial Review
Slide 10: Q2(19) net sales SEK37.3m – All time high
Q2(19) net sales SEK37.3m – All time high +32% Net Sales Q2 +9% LTM from Q1 10
Slide 11: North America – Showing growth Y/Y
North America – Showing growth Y/Y Apr-Jun (SEKm) 2019 2018 Net Sales 14.8 14.0 Net sales Gross profit 13.4 12.4 Q2 SEK14.8m Contribution (i) -23.4 -5.9 (i) Contribution in the period was affected by a non comparability item with a negative impact of SEK 11.0 million. +6% Net Sales Q2 11
Slide 12: EUROW – strong Y/Y growth – driven by CERAMENT G & V
EUROW – strong Y/Y growth – driven by CERAMENT G & V Jan-Mar (SEKm) 2019 2018 59% Net Sales Net Sales 22.5 14.2 Q2 Gross profit 18.8 12.2 Contribution 3.8 -1.0 12
Slide 13: Well funded to profitability
Well funded to profitability Key Figures 2019 2018 2017 SEK m Q2 (ii) Q1 Q4 Q3 (i) Q2 Q1 Q4 Q3 Net Sales 37,3 32,8 23,1 14,2 28,2 31,1 27,0 32,7 Gross Margin (%) 86,5 85,9 85,0 81,8 87,4 82,1 83,3 87,8 Operating Loss -47,8 -39,0 -45,0 -58,4 -37,8 -33,1 -33,4 -20,1 Cash at period end 173,1 219,1 261,
Slide 14: Focused investments in commercial acceleration
Focused investments in commercial acceleration Key Figures 2019 2018 2017 SEK m Q2 (i) Q1 Q4 Q3 Q2 Q1 Q4 Q3 Selling expenses 52,7 40,8 38,8 35,1 31,8 27,6 21,5 24,4 Research and 16,0 16,9 17,6 16,4 17,2 14,8 19,7 12,8 Development expenses Administrative expenses 10,5 10,4 9,3 17,5 14,9 16,5 15,5 11,
Slide 15: Clear Corporate Goals to Drive Value
Clear Corporate Goals to Drive Value
Slide 16: Delivering on updated strategy
Delivering on updated strategy • Expect an increasing trend Q/Q in EU and US leading to a significant uplift in sales in 2019 ‒ Market access success in the US ‒ Bigger, more focused European sales team in place ‒ Health Economic Data coming Q3 ‒ Growing base of solid clinical evidence showing the u
Slide 17: Value driving milestones for CERAMENT
Value driving milestones for CERAMENT® Q3 2019 CERAMENT®|G Canada Launch Q1 2019 May 20th ZB not 2020 2021 BONIFY permitted to sell CERAMENT®|G CERAMENT®|G Launch CERAMENT – PMA Filing US Approval 2019 2020 2021 2022 Q1 2019 H2 2019 2022 Q3 2019 2020: SOLARIO FORTIFY Patient SOLARIO Health FORTIFY S
Slide 18: Q&A
Q&A